The Effects of Programmed Death-ligand 1 on Postoperative Pain for Lung Cancer Patients

NCT ID: NCT06503432

Last Updated: 2024-09-19

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 100 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-07-20
• Study Completion Date: 2025-03-31

Brief Summary

The concentration of plasma programmed death-ligand 1(PD-L1) for lung cancer patients before video-assisted thoracoscopic surgery is detected. According to the distribution of plasma concentration, patients are divided into high or low expression of PD-L1. Differences in acute and chronic postoperative pain are compared between two groups of patients. And effects of PD-L1 expresion on postoperative pain in lung cancer patients are explained.

Detailed Description

Chronic pain after video-assisted thoracoscopic surgery (VATS) has been a major concern for lung cancer patients. The relationship between plasma programmed cell death ligand-1 (PD-L1) concentration and chronic pain in post-VATS is uncertain. This study aims to explore the effects of PD-L1 levels on chronic pain and provide proactive pain management regimen according to individual genetic differences.

The concentration of plasma PD-L1 for lung cancer patients before video-assisted thoracoscopic surgery is detected. According to the distribution of plasma concentration, patients are divided into high or low expression of PD-L1. Differences in acute and chronic postoperative pain are compared between two groups of patients. And effects of PD-L1 expresion on postoperative pain in lung cancer patients are explained.

Conditions

Lung Cancer; Postoperative Pain

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

high expression of programmed death-ligand 1

According to the distribution of PD-L1 concentration levels in the plasma, participants were divided into two groups: high expression of PD-L1 (PD-L1(H)) and low expression of PD-L1 (PD-L1(L)).

No interventions assigned to this group

low expression of programmed death-ligand 1

According to the distribution of PD-L1 concentration levels in the plasma, participants were divided into two groups: high expression of PD-L1 (PD-L1(H)) and low expression of PD-L1 (PD-L1(L)).

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

1. American Society of Anesthesiologists physical status I-IV (males and females).

2. 18-80 years of age.

3. Patients undergoing video-assisted thoracoscopic surgery for malignant lung disease.

Exclusion Criteria

1. History of opioid abuse.

2. Known psychiatric disorders.

3. Unexpected conversion to thoracotomy or transferred to intensive care unit for further treatment.

4. Combined with other surgeries or sites.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Peking University People's Hospital

OTHER

Sponsor Role: lead

Responsible Party

Yi Feng, MD

director of department of Anesthesiology and Pain medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Xue Tian, MD

Role: PRINCIPAL_INVESTIGATOR

Peking University People's Hospital

Locations

Peking University People's Hospital

Beijing, Beijing Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Xue Tian, MD

Role: CONTACT

justine_troy@163.com

88325581

Facility Contacts

Yi Feng, MD

Role: primary

Other Identifiers

2020PHB252-01

Identifier Type: -

Identifier Source: org_study_id